Please use this identifier to cite or link to this item: http://e.ieu.edu.ua/handle/123456789/764
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMATUSZEWSKI, Michal-
dc.contributor.authorPRUC, Michal-
dc.contributor.authorSZARPAK, Lukasz-
dc.contributor.authorNavolokina, Alla-
dc.contributor.authorKIEZUN, Katarzyna-
dc.contributor.authorChirico, Francesco-
dc.contributor.authorNUCERA, Gabriella-
dc.contributor.authorStepanovskyy, Yuriy-
dc.contributor.authorYILDIRIM, Murat-
dc.contributor.authorHilfanova, Anna-
dc.contributor.authorBondarenko, Anastasiia-
dc.date.accessioned2024-01-04T19:15:30Z-
dc.date.available2024-01-04T19:15:30Z-
dc.date.issued2023-03-15-
dc.identifier.citationMatuszewki M, Pruc M, Szarpak L, Navolokina A, Kiezun K, Chirico F, Nucera G, Stepanovskyy Y, Yildirim M, Hilfanova A, Bondarenko A. A comprehensive review and metaanalysis of the relationships between interleukin-7 levels and COVID-19 severity. J Health Soc Sci. 2023; 8(1):33-44. Doi:10.19204/2023/acmp3uk
dc.identifier.urihttp://e.ieu.edu.ua/handle/123456789/764-
dc.description.abstractIntroduction: As the major mechanism for coronavirus disease 2019, cytokine storm-mediated organ harm continues to dominate current understanding. Despite the first hyper-inflammatory phase, emerging data show that virus-induced poor host immunity may be the true cause of mortality in many individuals. Interleukin 7 (IL-7) is an interleukin that participates in the COVID-19 cytokine storm and regulates the immune system. Its role in COVID-19 cytokine storms is thought to be related to its ability to stimulate the formation and activation of immune cells such as T cells and B cells. This meta-analysis aims to determine the relationship, if any, between interleukin-7 and COVID-19 severity. Methods: This study was planned as a systematic review and meta-analysis and followed the PRISMA guidelines. Four main electronic databases (Web of Science, PubMed, Scopus, and the Cochrane Central Register of Controlled Trials) were searched from January 1st, 2020 to September 2nd, 2022, to find papers investigating the prognostic significance of interleukin-7 in COVID-19- hospitalized adults. Google Scholar was used in addition to the online database search. A random effects model was used to calculate mean differences and 95% confidence interval (CIs) as well as the I2 statistics for heterogeneity analysis. Results: Seven papers were chosen for meta-analysis findings synthesis. All six trials reported interleukin-7 levels among severe and non-severe COVID-19 patients. Pooled analysis showed that IL-7 levels in the severe group were 62.79±81.03 pg/mL, compared to 33.39±56.54 pg/mL for the nonsevere group (SMD = -0.17; 95%CI: -0.93 to 0.60; p=0.67). Discussion: Available evidence suggests that elevated levels of IL-7 were not associated with the disease severity of COVID-19. While IL-7 levels alone may not have a substantial impact on COVID19 severity, the interaction between IL-7 and other cytokines, immune cells, and variables such as viral load and genetics should be investigated further. Take-home message: This meta-analysis found that there was no strong link between levels of interleukin-7 and the severity of COVID-19. However, further research is needed to explore the interaction between IL-7 and other factors such as cytokines, immune cells, viral load, and genetics in order to better understand the role of IL-7 in COVID-19 pathogenesis.uk
dc.language.isoenuk
dc.publisherJournal Health and Social Sciencesuk
dc.relation.ispartofseriesJ Health Soc Sci;2023, 8, 1, 33-44.-
dc.subjectinterleukin 7uk
dc.subjectcytokine stormuk
dc.subjectSARS-CoV-2uk
dc.subjectCOVID-19uk
dc.subjectseverityuk
dc.subjectmeta-analysisuk
dc.titleA comprehensive review and meta-analysis of the relationships between interleukin-7 levels and COVID-19 severityuk
dc.typeArticleuk
Appears in Collections:Європейська медична школа

Files in This Item:
File Description SizeFormat 
Matuszewskietal33_44March2023JHSS1.pdf892.63 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.